HR 1143 · in committee · significant
Medicare IVIG Access Enhancement Act of 2025
- healthcare
What this bill does
- Medicare will cover intravenous immune globulin treatment administered at home for certain nerve diseases.
- Patients with chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy gain access to home-based treatment.
- Coverage begins upon enactment with no specified cost offset or implementation timeline.
Generated by claude-haiku-4-5
Community Threads
Started by Cosponsor
- 01
How might expanding Medicare coverage for home-based IVIG treatment affect total program costs, and should Congress identify offsetting budget reductions?
- 02
Which patients currently lack access to IVIG therapy due to Medicare's coverage limitations, and what barriers prevent them from receiving treatment?
- 03
What evidence demonstrates that administering IVIG at home produces comparable health outcomes to hospital or clinic-based administration for these neurological conditions?
Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.
Sponsor · R-NE-3
Adrian Smith
Citizen cosponsors
0
In Congress
2/ 435
House Reps cosponsoring
Introduced 2025-02-07
Joining the bill
Legislative timeline
2025-02-07 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-07 · house · IntroReferral
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
2025-02-07 · IntroReferral
Introduced in House
2025-02-07 · IntroReferral
Introduced in House
Citizen comments
Sign in to comment on this bill.
No comments yet — be the first.